BOULDER, Colo. – Dec. 3, 2013– Clovis Oncology, Inc. (Nasdaq: CLVS) announced today the pricing
of an underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $57.50 per share. All of the
shares are being sold by certain existing stockholders who acquired the shares of the Company’s common stock as consideration
in connection with the Company’s acquisition of EOS (Ethical Oncology Science) S.p.A.
J.P. Morgan Securities LLC is acting as the sole manager for the offering. The selling stockholders have granted J.P. Morgan
Securities a 30-day option to purchase up to an additional 300,000 shares of common stock from the selling stockholders to
cover over-allotments, if any. All net proceeds from the sale of the common stock will be received by the selling stockholders.
The Company will not receive any of the proceeds, and the total number of shares of its outstanding common stock will not
change as a result of the offering.
The shares of common stock are being sold by the selling stockholders pursuant to an effective shelf registration statement. This
offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling
toll-free (866) 803-9204. The offering is expected to close on December 9, 2013, subject to customary closing conditions.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other jurisdiction.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anticancer
agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific
subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the
population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional
offices in San Francisco, California and Cambridge, UK.
Source: Clovis Oncology, Inc.
Clovis Oncology, Inc.
Anna Sussman, 303-625-5022
Breanna Burkart, 303-625-5023